Absence of gut microbiota restoration following meropenem treatment in a systemic infection model
Antibiotics have been shown to have unintended effects on the host by disrupting the beneficial microbiota. In this study, we explored and longitudinally monitored microbiota during and after antibiotic treatment for infection. We induced a systemic Escherichia coli infection in 45 BALB/c mice, with 25 as uninfected controls. The disease was treated with meropenem. The animals were evaluated longitudinally three times, including 3 hours, five days of treatment, and 30 days post-treatment. Intestinal, lung, blood, and peritoneal lavage samples were collected for analysis. Our findings show that meropenem effectively treated the lethal systemic infection caused by E. coli. Hematological parameters, crypt depth, and goblet cell numbers remained unchanged for 30 days post-antibiotic treatment. However, antibiotic treatment impaired the recovery of the gut microbiota, even 30 days post-treatment. This long-term meropenem impact on microbiota was observed in both infected and non-infected (saline-treated) groups. Alpha and beta diversity analyses did not indicate a microbiota recovery. Notably, Lactobacillus and Bacteroides decreased, while Clostridioides, Enterococcus, and Escherichia-Shigella increased. This study provides novel evidence that, even 30 days after meropenem treatment in a simulated E. coli infection, the intestinal microbiota does not recover, highlighting prolonged antibiotic-induced dysbiosis.
Authors
- Rosângela dos Santos Ferreira (ORCID: https://orcid.org/0000-0001-6965-6639)
- César de la Fuente‐Núñez (ORCID: https://orcid.org/0000-0002-2005-5629)
- Octávio Luiz Franco (ORCID: https://orcid.org/0000-0001-9546-0525)
- Gislaine Greice de Oliveira Silva Silveira (ORCID: https://orcid.org/0000-0002-5385-518X)
- Osmar Nascimento Silva (ORCID: https://orcid.org/0000-0003-2148-131X)
- Gisele Braziliano de Andrade (ORCID: https://orcid.org/0000-0001-6289-9945)
- Sarah Saory Makimoto
- Filipe M. Ribeiro (ORCID: https://orcid.org/0000-0003-4141-6830)
- Franciele Bathel da Mota
- Camila Fontoura Acosta Ribeiro (ORCID: https://orcid.org/0000-0001-5503-0002)
- Marlon Henrique e Silva Cardoso (ORCID: https://orcid.org/0000-0001-6676-5362)
- Cristiano Marcelo Espínola Carvalho (ORCID: https://orcid.org/0000-0002-3867-9528)
- Elizabete de Souza Cândido (ORCID: https://orcid.org/0000-0002-3126-029X)
- Alinne Pereira de Castro (ORCID: https://orcid.org/0000-0002-9703-0577)
- Alanderson Rodrigues da Silva (ORCID: https://orcid.org/0000-0001-5560-1098)
- Danieli Fernanda Buccini (ORCID: https://orcid.org/0000-0001-6381-3779)
- Carolina Melo de Souza
- N.C. Oliveira (ORCID: https://orcid.org/0000-0002-6150-4427)
Institutions
- Universidade Católica de Brasília (BR)
- Universidade Evangelica de Goiás (BR)
- Centro Universitário do Distrito Federal (BR)
- Universidade Católica Dom Bosco (BR)
Publication Details
- Journal
- npj Antimicrobials and Resistance
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1038/s44259-025-00129-9
- Citations
- 2
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Brain and Behavior Research Foundation
- International Association for Dental Research
- University of Pennsylvania
- United Therapeutics Corporation
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Financiadora de Estudos e Projetos
- Fundação de Apoio à Pesquisa do Distrito Federal
- Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul
- National Institutes of Health
- Defense Threat Reduction Agency
- Perelman School of Medicine, University of Pennsylvania
- National Institute of General Medical Sciences